← Ticker index
NBIX
Ticker
NBIX
Congressional Trades
10
by 2 members
Ticker disclosure brief
Congressional disclosure records for NBIX
A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.
Latest receipt
Lisa McClain
SELL · 2025-06-17
Largest range
$15K – $50K
Michael McCaul
Longest observed gap
64d
Lisa McClain
Highest 30d vs SPY
19.3%
Michael McCaul
Purchase rows
3
30%
Sale rows
7
70%
Disclosed midpoint
$129K
range estimate
Unique Traders
2
members
Disclosure timing method
Observed filing gaps are not notice-date findings
The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.
Party Breakdown
Democrats0 · 0%
Republicans10 · 100%
Federal awards
all →- 2026-05-27$0Department of Veterans Affairs65 I B, DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS, FSS CONTRACT AWARD
Lobbying filings
all →- 2026-07-08$60KNEUROCRINE BIOSCIENCES INC.Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare
- 2026-04-20$940KNEUROCRINE BIOSCIENCES INCIssues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit. Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program. Support appropriations report language and funding to encourage addition
- 2026-04-20$80KNEUROCRINE BIOSCIENCES INC.IRA, prescription drug pricing, payment reform, innovation telehealth, mental health, prescription drug pricing, payment reform federal budget issues
- 2026-04-20$60KNEUROCRINE BIOSCIENCES INC.Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
- 2026-04-17$30KNEUROCRINE BIOSCIENCES INC.General Medicare and Medicaid Issues. Prescription drug payment reform. Pharmaceutical supply chain.
- 2026-04-16$60KNEUROCRINE BIOSCIENCES INC.Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare
- 2026-01-20$900KNEUROCRINE BIOSCIENCES INCIssues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program. Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services for physical conditions associated with mental illness, such as Tardive Dyskinesia. Issues related to the Research and Development (R
- 2026-01-20$80KNEUROCRINE BIOSCIENCES INC.IRA, prescription drug pricing, payment reform, innovation telehealth, mental health, prescription drug pricing, payment reform federal budget issues
- 2026-01-20$60KNEUROCRINE BIOSCIENCES INC.Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
- 2026-01-18$60KNEUROCRINE BIOSCIENCES INC.Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare
Loading trade analytics…
All Disclosed Trades
Page 1 · 10 of 10 shown| Date | Member | Action | Amount | Observed Gap | Receipt |
|---|---|---|---|---|---|
| 2025-06-17 | RLisa McClain | SELL | $1K – $15K | 58dApparent delay | receipt → |
| 2025-06-11 | RLisa McClain | BUY | $1K – $15K | 64dApparent delay | receipt → |
| 2025-06-11 | RLisa McClain | BUY | $1K – $15K | 63dApparent delay | receipt → |
| 2025-06-17 | RLisa McClain | SELL | $1K – $15K | 57dApparent delay | receipt → |
| 2025-06-11 | RLisa McClain | BUY | $1K – $15K | 63dApparent delay | receipt → |
| 2025-06-17 | RLisa McClain | SELL | $1K – $15K | 57dApparent delay | receipt → |
| 2024-11-19 | RMichael McCaul | SELL | $15K – $50K | 27d | receipt → |
| 2024-11-19 | RMichael McCaul | SELL | $15K – $50K | 27d | receipt → |
| 2024-08-26 | RMichael McCaul | SELL | $1K – $15K | 21d | receipt → |
| 2024-08-26 | RMichael McCaul | SELL | $1K – $15K | 21d | receipt → |
“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.